Form 8-K - Current report:
SEC Accession No. 0001104659-24-112053
Filing Date
2024-10-29
Accepted
2024-10-29 08:05:24
Documents
15
Period of Report
2024-10-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2426946d1_8k.htm   iXBRL 8-K 42886
2 EXHIBIT 2.1 tm2426946d1_ex2-1.htm EX-2.1 218732
3 EXHIBIT 4.1 tm2426946d1_ex4-1.htm EX-4.1 162734
  Complete submission text file 0001104659-24-112053.txt   694743

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA immu-20241025.xsd EX-101.SCH 3015
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE immu-20241025_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE immu-20241025_pre.xml EX-101.PRE 22359
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2426946d1_8k_htm.xml XML 3688
Mailing Address 18702 N. CREEK PARKWAY SUITE 100 BOTHELL WA 98011
Business Address 18702 N. CREEK PARKWAY SUITE 100 BOTHELL WA 98011 610-321-3700
Immunome Inc. (Filer) CIK: 0001472012 (see all company filings)

EIN.: 770694340 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39580 | Film No.: 241402738
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)